Vonoprazan Dosing and Management for Erosive Esophagitis
For mild erosive esophagitis (LA grade A/B), start with standard-dose PPIs first; reserve vonoprazan 20 mg once daily for 8 weeks only if twice-daily PPIs fail, then maintain with 10 mg once daily for up to 6 months. For severe erosive esophagitis (LA grade C/D), vonoprazan may be used as first-line therapy given its superior healing and maintenance rates compared to PPIs 1, 2.
Treatment Algorithm by Disease Severity
Mild Erosive Esophagitis (LA Grade A/B)
- First-line: Standard-dose PPI (e.g., lansoprazole 30 mg once daily)
- Second-line: If inadequate response, escalate to twice-daily PPI
- Third-line: If twice-daily PPI fails with confirmed GERD (LA grade B or greater, Barrett's esophagus, peptic stricture, or acid exposure time >6% on pH monitoring), switch to vonoprazan 20 mg once daily 1
The rationale is straightforward: healing rates for LA grade A/B are similar between vonoprazan and PPIs (92-99% vs 96-100%), making the markedly higher cost of vonoprazan unjustifiable as first-line therapy 1. The 2024 AGA guidelines explicitly state vonoprazan should not be first-line for milder disease 1.
Severe Erosive Esophagitis (LA Grade C/D)
Vonoprazan demonstrates clear superiority here and may be used first-line:
Healing phase: Vonoprazan 20 mg once daily for up to 8 weeks 2
- At week 2, vonoprazan heals 17.6% more LA grade C/D cases than lansoprazole (difference 17.6%; 95% CI: 7.4%-27.4%) 3
Maintenance phase: Vonoprazan 10 mg once daily for up to 6 months 2
The evidence strongly favors vonoprazan in severe disease, with a US/European trial showing 13.3% absolute improvement in maintenance of healing for LA grade C/D (75% vs 61%, p=0.02) 1, 3.
Practical Dosing Details
Healing Phase:
- Vonoprazan 20 mg once daily with or without food
- Swallow whole; do not chew or crush
- Duration: up to 8 weeks 2
- Endoscopic reassessment at 2 or 8 weeks to confirm healing
Maintenance Phase:
- Vonoprazan 10 mg once daily
- FDA-approved for up to 6 months 2
- The 20 mg maintenance dose showed no additional benefit over 10 mg 2, 3
Special Populations
Renal/Hepatic Impairment: Dosage adjustments may be needed—consult full prescribing information 2
Hiatus Hernia: Recent data shows vonoprazan efficacy is reduced in patients with hiatus hernia (60% complete healing vs 96% without hernia), though still effective 4. Consider this when setting expectations.
Common Pitfalls and Caveats
Cost Considerations: Vonoprazan costs significantly more than generic PPIs, requires prior authorization, and lacks over-the-counter availability 1. Even with modest clinical superiority, cost-effectiveness for mild disease is questionable 1.
Long-term Safety: While 5-year data shows no malignant changes or gastric NETs, vonoprazan causes higher rates of parietal cell hyperplasia (97% vs 87%), foveolar hyperplasia (15% vs 2%), and elevated gastrin levels (625 vs 200 pg/mL) compared to lansoprazole 5. Clinical significance remains uncertain, but this warrants monitoring in long-term use.
Not Superior to Double-Dose PPIs: The guidelines emphasize that vonoprazan has not been compared to twice-daily PPIs in randomized trials 1. This is a critical gap—always try optimized PPI therapy (twice daily) before switching to vonoprazan for cost and safety reasons.
Timing of Endoscopy: For LA grade C/D, consider early endoscopy at week 2, as vonoprazan shows significantly faster healing than PPIs at this timepoint 3.
When to Avoid Vonoprazan First-Line
- Uninvestigated heartburn or nonerosive reflux disease 1
- LA grade A/B erosive esophagitis without prior PPI failure 1
- Peptic ulcer disease (no demonstrated superiority) 1
- Cost-sensitive situations where PPIs are effective
Monitoring During Maintenance
- Reassess appropriateness and dosing within 12 months if continuing therapy 6
- Consider endoscopy with prolonged wireless pH monitoring off medication to establish need for long-term therapy 6
- Monitor for adverse events (similar rates to PPIs: ~10-11%) 7
- Real-world data suggests vonoprazan reduces hospitalizations (HR 0.28) and bleeding (HR 0.36) compared to PPIs 8
Bottom line: Vonoprazan's role is clearest in severe erosive esophagitis (LA grade C/D) and PPI-refractory disease with confirmed acid-related pathology. For mild disease, exhaust PPI options first given cost, availability, and lack of long-term safety data 1.